Elimination of Disparities in the Era of Precision Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Elimination of Disparities in the Era of Precision Oncology

Focusing on Your Primary Care Contribution, The Jane Cooke Wright, MD, Oncology Symposium

Not a member of My prIME? Join now for instant access.

Downloadable slides from Elimination of Disparities in the Era of Precision Oncology: Focusing on Your Primary Care Contribution, a prIME Oncology symposium held at the National Medical Association Annual Meeting focusing on the role of the primary care physician in helping to eliminate disparities in cancer care.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Aug 20, 2018

Expiration Date

Aug 20, 2019

Featured Expert

  • Edith P. Mitchell, MD, FACP, FCPP, Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Featured Topic

Keynote presentation: Precision oncology; Today and tomorrow

Featured Expert

  • Worta J. McCaskill-Stevens, MD, MS, National Cancer Institute , Rockville, Maryland, United States

Featured Topic

Breast cancer

Featured Expert

  • Douglas R. Lowy, MD, National Cancer Institute, Bethesda, Maryland, United States

Featured Topic

Human papilloma virus-related cancers

Featured Expert

  • Jhanelle E. Gray, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Featured Topic

Non-small cell lung cancer

Featured Expert

  • Durado D. Brooks, MD, MPH , American Cancer Society , Atlanta, Georgia, United States

Featured Topic

Colorectal cancer

Featured Expert

  • Edith P. Mitchell, MD, FACP, FCPP, Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Featured Topic

prIME Points™

This educational activity is specifically designed to meet the needs of internists, general practitioners, surgeons, obstetricians/gynecologists, pulmonologists, and other healthcare providers involved in the diagnosis, treatment, and/or follow-up of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Employ current evidence-based best practices for using screening and diagnostic tools for various malignancies in order to decrease the incidence of disparities
  • Assess the implications of disparities in the management of breast cancer, non-small cell lung cancer, colorectal cancer, and HPV-related cancers, and implement strategies to improve outcomes

This educational activity is supported by grants from Bristol-Myers Squibb and Merck and Co, Inc.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity

Dr Brooks has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gray has disclosed that she is an independent contractor for AstraZeneca, Genentech, and Boehringer Ingelheim. She is also a member on an advisory committee or review panel for AstraZeneca. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lowy disclosed as part of his US government supported research at the National Cancer Institute/National Institutes of Health, he is the inventor of technology that underlies the L1-based prophylactic virus-like particle (VLP) HPV vaccine and technology that underlies an L2-based candidate prophylactic HPV vaccine. The NIH has licensed the technology for the L1 VLP vaccine to Merck, the manufacturer of quadrivalent and nonavalent HPV vaccines, to GlaxoSmithKline, the manufacturer of bivalent HPV vaccine, and to Indian Immunologicals Ltd. The L2-based vaccine technology is the subject of a cooperative research and development agreement between NCI, Johns Hopkins University, and Shantha Biotech, and has been licensed to Shantha, Pax Vax, Acambis Inc, and GSK. Dr. Lowy discloses receipt of a limited share of the royalties NIH receives for these technologies. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr McCaskill-Stevens has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Mitchell has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.